{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:40:44Z","timestamp":1790703644103,"version":"4.1.0"},"reference-count":142,"publisher":"American Society for Clinical Investigation","issue":"2","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:p>In recent decades, immunotherapeutic strategies have been used to treat a wide range of pathologies, many of which were previously incurable, such as cancer and autoimmune disorders. Despite this unprecedented success, a considerable number of patients fail to respond to currently approved immunotherapies or develop resistance over time. Therefore, there is an urgent need to develop the next generation of immune-targeted therapies. Various members of the Ig superfamily play essential roles in regulating leukocyte functions. One such group, the leukocyte Ig-like receptors (LILRs), have been implicated in both innate and adaptive immune regulation. Human inhibitory LILRs (LILRBs) are primarily expressed on leukocytes and mediate their signaling through multiple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs. Engagement of LILRBs by endogenous and pathogenic ligands can markedly suppress immune responses, leading to tolerance or immunoevasion, whereas blocking these inhibitory receptors can potentiate immune responses. In this Review, we discuss the immunoregulatory functions of human LILRBs and the potential of targeting them to manipulate immune responses in various pathologies.<\/jats:p>","DOI":"10.1172\/jci.insight.151553","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T14:00:46Z","timestamp":1643032846000},"source":"Crossref","is-referenced-by-count":40,"title":["Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy"],"prefix":"10.1172","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6513-119X","authenticated-orcid":true,"given":"Calvin D.","family":"De Louche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-4218","authenticated-orcid":true,"given":"Ali","family":"Roghanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03158"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01668"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0588-4"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0394-3"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.003"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01290"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201746984"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2023-x"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2015.64"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.11.1809"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270313"},{"key":"B13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0065-2776(06)91007-4","article-title":"Inhibition of inflammatory responses by leukocyte Ig-like receptors","volume":"91","author":"Katz","year":"2006","journal-title":"Adv Immunol"},{"issue":"7","key":"B14","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.160.7.3096","article-title":"Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules","volume":"160","author":"Colonna","year":"1998","journal-title":"J Immunol"},{"issue":"1","key":"B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.162.1.5","article-title":"Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain","volume":"162","author":"Nakajima","year":"1999","journal-title":"J Immunol"},{"issue":"1","key":"B16","first-page":"16","article-title":"Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer","volume":"4","author":"Deng","year":"2021","journal-title":"Antib Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4742"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01162.x"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2001.1810103.x"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1121324"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni760"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205785109"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089771"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803277"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(10)60050-2"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737515"},{"issue":"18","key":"B27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141593","article-title":"LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation","volume":"5","author":"Yeboah","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"B28","first-page":"3149","article-title":"LILRB4, from the immune system to the disease target","volume":"12","author":"Liu","year":"2020","journal-title":"Am J Transl Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1259-z"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5MR1216-534R"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2021.05.011"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00692"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636031"},{"issue":"121","key":"B36","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000645","article-title":"Dynamics of subsynaptic vesicles and surface microclusters at the immunological synapse","volume":"3","author":"Purbhoo","year":"2010","journal-title":"Sci Signal"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0004-z"},{"issue":"5","key":"B38","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12804","article-title":"The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy","volume":"90","author":"Zhao","year":"2019","journal-title":"Scand J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.744"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109863"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000515"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445353"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3518"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300438"},{"issue":"6","key":"B45","first-page":"705","article-title":"Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes","volume":"12","author":"Merlo","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801472"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701622"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692954"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4202"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00191-7"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-549162"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature11095"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4217"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.3029"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2015.06.037"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97570"},{"issue":"6","key":"B58","first-page":"1943","article-title":"Immunoglobulin\u2011like transcript 4 and human leukocyte antigen\u2011G interaction promotes the progression of human colorectal cancer","volume":"54","author":"Cai","year":"2019","journal-title":"Int J Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1342023"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.11.008"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.02.012"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001536"},{"issue":"suppl 4","key":"B63","article-title":"5240 initial results of a phase I study of MK-4830, a first-in-class anti-immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients with advanced solid tumours","volume":"31","author":"Siu","year":"2020","journal-title":"Ann Oncol"},{"key":"B64","unstructured":"Merck Sharp & Dohme Corp. Study of MK-4830 as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-4830-001). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03564691 Updated November 12, 2021. Accessed December 7, 2021"},{"key":"B65","unstructured":"Jounce Therapeutics. Study of JTX 8064, as monotherapy and in combination with a PD-1 inhibitor, in adult subjects with advanced refractory solid tumors. https:\/\/ClinicalTrials.gov\/show\/NCT04669899 Updated July 23, 2021. Accessed December 7, 2021"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6905"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1573"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91015-6"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.048"},{"issue":"4","key":"B70","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","article-title":"ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells","volume":"19","author":"Singh","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"6","key":"B71","first-page":"697","article-title":"Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3)","volume":"8","author":"Cortesini","year":"2007","journal-title":"JOP"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.7432"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700553"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.007"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21952"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21050"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0036"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.08.001"},{"issue":"11","key":"B80","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0615-z"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0321-2"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00262-0"},{"key":"B84","unstructured":"Immune-Onc Therapeutics Inc. IO-202 as monotherapy in patients in AML and CMML. https:\/\/ClinicalTrials.gov\/show\/NCT04372433 Updated September 16, 2021. Accessed December 7, 2021"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/v12091051"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature04946"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-10-56"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717998"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3812"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2530-3"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2021.02.033"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nature24994"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4250"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/srep21780"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz319"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70265-7"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900852"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/srep35085"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317454111"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/srep40923"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01009-10"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-122"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80529-4"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4473"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5629"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12855-3"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/90935"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78088"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.279"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.294"},{"issue":"2","key":"B113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12016-009-8148-8","article-title":"Leukocyte immunoglobulin-like receptors as new players in autoimmunity","volume":"38","author":"Thomas","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"B114","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4049\/jimmunol.2000265","article-title":"Suppression of experimental autoimmune encephalomyelitis by ILT3.Fc","volume":"206","author":"Xu","year":"2020","journal-title":"J Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701450"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123838"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M512305200"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.159673"},{"issue":"2","key":"B119","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2007.05.003","article-title":"Analysis of expression and function of the inhibitory receptor ILT2 (CD85j\/LILRB1\/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE)","volume":"29","author":"Monsiv\u00e1is-Urenda","year":"2007","journal-title":"J Autoimmun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199303000-00005"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.09.001"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.07.001"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.05.006"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.inmuno.2011.06.004"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092018"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-021-00906-0"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/art.39035"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00119-6"},{"issue":"10","key":"B129","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015479","article-title":"The innate immune system and transplantation","volume":"3","author":"Farrar","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.31729\/jnma.3375"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318186fccd"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4103\/2319-4170.131376"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0835"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2011.10.001"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0054"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.06.001"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3109\/08830180903281185"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.10.012"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2006.10.017"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-183814"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-557645"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvx036"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/151553\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:39:14Z","timestamp":1779147554000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/151553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":142,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,1,25]]}},"alternative-id":["10.1172\/jci.insight.151553"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.151553","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"article-number":"e151553"}}